MedTrace Logo

Glivec in Ph Positive Lymphoblastic Leukemia

NCT00388895 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2008-11-19

No results posted yet for this study

Summary

% positive Ph LLA with RC alter the Glivec and induction chemotherapy treatment

Conditions

Interventions

DRUG

chemotherapy

DRUG

Glivec

Sponsors & Collaborators

  • PETHEMA Foundation

    lead OTHER

Principal Investigators

  • Ribera Josep Mª, Dr · Germans Trias i Pujol Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-06-30
Primary Completion
2006-10-31
Completion
2007-10-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00388895 on ClinicalTrials.gov